Cargando…

A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin

OBJECTIVE: To assess the efficacy of Imedeen Time Perfection for improving the appearance and condition of photoaged skin in healthy women. METHODS: This randomized, double-blind, placebo-controlled clinical trial enrolled healthy women, 35–60 years of age, with Fitzpatrick I–III and Glogau II–III s...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephens, Thomas J, Sigler, Monya L, Herndon, James H, Dispensa, Lisa, Le Moigne, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801055/
https://www.ncbi.nlm.nih.gov/pubmed/27042135
http://dx.doi.org/10.2147/CCID.S98787
_version_ 1782422540646350848
author Stephens, Thomas J
Sigler, Monya L
Herndon, James H
Dispensa, Lisa
Le Moigne, Anne
author_facet Stephens, Thomas J
Sigler, Monya L
Herndon, James H
Dispensa, Lisa
Le Moigne, Anne
author_sort Stephens, Thomas J
collection PubMed
description OBJECTIVE: To assess the efficacy of Imedeen Time Perfection for improving the appearance and condition of photoaged skin in healthy women. METHODS: This randomized, double-blind, placebo-controlled clinical trial enrolled healthy women, 35–60 years of age, with Fitzpatrick I–III and Glogau II–III skin types and mild-to-moderate facial fine lines/wrinkles. The eligible subjects were randomized to receive two tablets daily of either Imedeen Time Perfection (Imedeen) or a matching placebo for 12 weeks. Efficacy assessments included investigator rating of 16 photoaging parameters (ie, global facial appearance and 15 individual facial parameters and the average of all parameters), instrumentation (ie, ultrasound dermal density, moisture level of the stratum corneum, transepidermal water loss, cutometry), and subjects’ self-assessment. Differences in the mean change from baseline to week 12 values on these outcomes were compared between Imedeen and placebo using analysis of variance or a paired t-test. RESULTS: Seventy-four subjects with primarily Fitzpatrick skin type III (78%–79%) and Glogau type III (53%–58%) completed the study (Imedeen: n=36; placebo: n=38). The mean difference in change from baseline to week 12 for global facial assessment significantly favored Imedeen over placebo (−0.52; P=0.0017). Additionally, the mean differences in the average of all facial photoaging parameters (−0.29), mottled hyperpigmentation (−0.25), tactile laxity (−0.24), dullness (−0.47), and tactile roughness (−0.62) significantly favored Imedeen over placebo (P≤0.05). Significantly greater increases in ultrasound dermal density (+11% vs +1%; P≤0.05) and stratum corneum moisturization (+30% vs +6%; P≤0.05) were also observed for Imedeen than for placebo. There were no significant differences on other instrumental outcomes. CONCLUSION: The results of this study suggest that Imedeen Time Perfection can positively affect the appearance of photoaged skin, moisturization, and skin density over 12 weeks of treatment.
format Online
Article
Text
id pubmed-4801055
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48010552016-04-01 A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin Stephens, Thomas J Sigler, Monya L Herndon, James H Dispensa, Lisa Le Moigne, Anne Clin Cosmet Investig Dermatol Original Research OBJECTIVE: To assess the efficacy of Imedeen Time Perfection for improving the appearance and condition of photoaged skin in healthy women. METHODS: This randomized, double-blind, placebo-controlled clinical trial enrolled healthy women, 35–60 years of age, with Fitzpatrick I–III and Glogau II–III skin types and mild-to-moderate facial fine lines/wrinkles. The eligible subjects were randomized to receive two tablets daily of either Imedeen Time Perfection (Imedeen) or a matching placebo for 12 weeks. Efficacy assessments included investigator rating of 16 photoaging parameters (ie, global facial appearance and 15 individual facial parameters and the average of all parameters), instrumentation (ie, ultrasound dermal density, moisture level of the stratum corneum, transepidermal water loss, cutometry), and subjects’ self-assessment. Differences in the mean change from baseline to week 12 values on these outcomes were compared between Imedeen and placebo using analysis of variance or a paired t-test. RESULTS: Seventy-four subjects with primarily Fitzpatrick skin type III (78%–79%) and Glogau type III (53%–58%) completed the study (Imedeen: n=36; placebo: n=38). The mean difference in change from baseline to week 12 for global facial assessment significantly favored Imedeen over placebo (−0.52; P=0.0017). Additionally, the mean differences in the average of all facial photoaging parameters (−0.29), mottled hyperpigmentation (−0.25), tactile laxity (−0.24), dullness (−0.47), and tactile roughness (−0.62) significantly favored Imedeen over placebo (P≤0.05). Significantly greater increases in ultrasound dermal density (+11% vs +1%; P≤0.05) and stratum corneum moisturization (+30% vs +6%; P≤0.05) were also observed for Imedeen than for placebo. There were no significant differences on other instrumental outcomes. CONCLUSION: The results of this study suggest that Imedeen Time Perfection can positively affect the appearance of photoaged skin, moisturization, and skin density over 12 weeks of treatment. Dove Medical Press 2016-03-15 /pmc/articles/PMC4801055/ /pubmed/27042135 http://dx.doi.org/10.2147/CCID.S98787 Text en © 2016 Stephens et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Stephens, Thomas J
Sigler, Monya L
Herndon, James H
Dispensa, Lisa
Le Moigne, Anne
A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin
title A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin
title_full A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin
title_fullStr A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin
title_full_unstemmed A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin
title_short A placebo-controlled, double-blind clinical trial to evaluate the efficacy of Imedeen(®) Time Perfection(®) for improving the appearance of photodamaged skin
title_sort placebo-controlled, double-blind clinical trial to evaluate the efficacy of imedeen(®) time perfection(®) for improving the appearance of photodamaged skin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801055/
https://www.ncbi.nlm.nih.gov/pubmed/27042135
http://dx.doi.org/10.2147/CCID.S98787
work_keys_str_mv AT stephensthomasj aplacebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT siglermonyal aplacebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT herndonjamesh aplacebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT dispensalisa aplacebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT lemoigneanne aplacebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT stephensthomasj placebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT siglermonyal placebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT herndonjamesh placebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT dispensalisa placebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin
AT lemoigneanne placebocontrolleddoubleblindclinicaltrialtoevaluatetheefficacyofimedeentimeperfectionforimprovingtheappearanceofphotodamagedskin